
|Articles|May 1, 2001
Steroid-sparing drugs needed to reduce risks
Dapsone, hydroxychloroquine, other agents help stem complications such as bone loss, cataracts, infections
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Transformative Advances This Year and Beyond
2
FDA Proposes Expansion of US Sunscreen Ingredient Standards with Bemotrizinol
3
"PDE4 Inhibitor-Responsive Dermatoses": A Modern Framework for Managing Inflammatory Skin Conditions
4
Meta-analysis Confirms Benefits of Roflumilast 0.3% Cream for PsO
5


















